Analysts are bullish on several healthcare stocks, with Merck & Company (MRK), Tarsus Pharmaceuticals (TARS), and Ascendis Pharma (ASND) receiving positive outlooks. Barclays analyst Emily Field maintained a Buy rating on Merck, setting a price target of $150.00. Merck’s shares closed at $145.60 last Friday. Field is a 3-star analyst with a 45.7% success rate. The consensus among analysts suggests a Moderate Buy for Merck, with an average price target of $159.52, indicating a 12.8% upside from current levels.
Tarsus Pharmaceuticals also received a Buy rating from Barclays analyst Jenna Davidner, who set a price target of $110.00. The stock closed at $73.16 last Friday. Davidner is a 1-star analyst with a 45.0% success rate. The general consensus on Tarsus is a Strong Buy, with an average price target of $101.50, suggesting a 40.5% upside.
Ascendis Pharma was reiterated as a Buy by J.P. Morgan analyst Jessica Fye, who closed last Friday at $229.23. Fye is a 4-star analyst with a 51.1% success rate. The consensus for Ascendis is also a Strong Buy, with an average price target of $318.31, indicating a 41.4% upside from current levels.